The mitochondria-targeted peptide SS-31 protected mouse hind limbs from ischemia-reperfusion injury by reducing oxidative stress, preserving mitochondrial function, suppressing inflammation, and preventing cell death — whether given before or after the injury.
Preventive and therapeutic efficacySS-31 protected against limb ischemia-reperfusion injury whether given before or after the ischemic event, with pre-treatment being mildly more effective
What the researchers found
SS-31 treatment conferred comprehensive protection against hind limb ischemia-reperfusion injury through multiple mechanisms:
- Reduced oxidative stress: lowered malondialdehyde levels and increased SOD and catalase activities and protein levels
- Protected mitochondria: preserved cellular ATP content and mitochondrial membrane potential, reduced cytosolic cytochrome c release
- Suppressed inflammation: prevented IR-induced increases in TNF-α and IL-1β
- Blocked apoptosis: maintained cleaved caspase-3 at very low levels
- Preserved tissue integrity: prevented histological deterioration seen in vehicle controls
Both pre-ischemia and post-ischemia SS-31 administration were effective, with pre-treatment showing mildly superior protection.
Why it matters
Limb ischemia-reperfusion injury is a major clinical problem in vascular surgery, organ transplantation, and trauma. Current treatment options are limited. SS-31 (also known as elamipretide) is one of the most advanced mitochondria-targeted peptides in clinical development, and this study adds limb protection to its growing list of potential applications. The finding that it works both preventively and therapeutically is particularly relevant for surgical settings.
How the study worked
C57BL/6 male mice underwent hind limb ischemia-reperfusion injury. SS-31 was administered either before ischemia (preventive) or after reperfusion (therapeutic). Outcomes included histopathological assessment, oxidative stress markers (malondialdehyde, SOD, catalase), mitochondrial function (ATP content, membrane potential, cytochrome c release), inflammatory cytokines (TNF-α, IL-1β), and apoptosis markers (cleaved caspase-3). Results were compared against vehicle-treated controls.
What this study cannot tell us
This was a mouse study, and ischemia-reperfusion dynamics in human limbs may differ significantly. Specific dosing details were not provided in the abstract. The study did not assess long-term functional recovery or potential adverse effects. The comparison between pre- and post-treatment was qualitative ('mildly more effective') without formal statistical comparison between timing groups.
How to read the evidence
This is a preclinical mouse study with comprehensive outcome measures covering oxidative stress, mitochondrial function, inflammation, and apoptosis. While thorough in its mechanistic characterization, clinical translation requires human studies.
When this study was published
Published in 2018, this study contributed to the growing evidence base for SS-31 (elamipretide) that has since led to clinical trials in humans for various mitochondrial dysfunction conditions.
The bigger picture
SS-31 (elamipretide) is at the forefront of mitochondria-targeted peptide therapeutics, with clinical trials for heart failure, mitochondrial myopathy, and other conditions. This study extends the evidence base to peripheral vascular ischemia-reperfusion injury, reinforcing the versatility of targeting mitochondrial oxidative stress as a therapeutic strategy. The multi-pathway protection (anti-oxidant, anti-inflammatory, anti-apoptotic) reflects the central role of mitochondria in tissue injury.
Questions still open
- Could SS-31 be administered prophylactically before vascular surgery to prevent reperfusion injury in human patients?
- What is the optimal dosing window for SS-31 in ischemia-reperfusion — how long after injury can treatment begin and still be effective?
- Does SS-31's protection extend to remote organ damage that often occurs after limb ischemia-reperfusion (lung, kidney injury)?
Common questions
What is SS-31 and how does it target mitochondria?
What is ischemia-reperfusion injury and why is it a problem?
Read the original research
Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury.
Journal of physiology and biochemistry, 74(2), 335-343
Citation
Cai, Jing; Jiang, Yu; Zhang, Meng; Zhao, Hongting; Li, Huihui; Li, Kuanyu; Zhang, Xin; Qiao, Tong. (2018). Protective effects of mitochondrion-targeted peptide SS-31 against hind limb ischemia-reperfusion injury.. Journal of physiology and biochemistry, 74(2), 335-343. https://doi.org/10.1007/s13105-018-0617-1